Citius, Novellus collaborate on novel stem-cell therapy for ARDS associated with COVID-19

Citius, Novellus collaborate on novel stem-cell therapy for ARDS associated with COVID-19

Source: 
Pharmaceutical Business Review
snippet: 


Citius Pharmaceuticals has entered into an exclusive six-month option agreement with Novellus subsidiary to licence novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19, the disease caused due to the novel coronavirus SARS-CoV-2.